MX2020012914A - Proteina andamio para la generacion de proteinas quimericas de union a antigeno. - Google Patents

Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Info

Publication number
MX2020012914A
MX2020012914A MX2020012914A MX2020012914A MX2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A MX 2020012914 A MX2020012914 A MX 2020012914A
Authority
MX
Mexico
Prior art keywords
scaffold protein
binding proteins
chimeric antigen
generating chimeric
conotoxin
Prior art date
Application number
MX2020012914A
Other languages
English (en)
Inventor
Navarro Alexei Fedorovish Licea
Espinoza Salvador Dueñas
Campos Liliana Noemí Sánchez
Original Assignee
Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese filed Critical Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese
Priority to MX2020012914A priority Critical patent/MX2020012914A/es
Priority to EP21898766.7A priority patent/EP4253399A1/en
Priority to US18/253,971 priority patent/US20230374072A1/en
Priority to PCT/MX2021/050077 priority patent/WO2022114946A1/es
Publication of MX2020012914A publication Critical patent/MX2020012914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una proteína de andamio de SEQ ID NO: 1 derivada de una conotoxina, que no presenta residuos de aminoácidos asociados a la actividad tóxica de la conotoxina, y que puede ser usada para la generación de proteínas quiméricas de entre 19 a 47 aminoácidos, insertándole entre sus aminoácidos 11 y 12, fragmentos de un CDR3 de un vNAR con afinidad por un antígeno específico.
MX2020012914A 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno. MX2020012914A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.
EP21898766.7A EP4253399A1 (en) 2020-11-27 2021-11-19 Scaffolding protein for generating antigen-binding chimeral proteins
US18/253,971 US20230374072A1 (en) 2020-11-27 2021-11-19 Scaffolding protein for generating antigen-binding chimeral proteins
PCT/MX2021/050077 WO2022114946A1 (es) 2020-11-27 2021-11-19 Proteína andamio para la generación de proteínas quiméricas de unión a antígeno

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Publications (1)

Publication Number Publication Date
MX2020012914A true MX2020012914A (es) 2022-05-30

Family

ID=81754659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012914A MX2020012914A (es) 2020-11-27 2020-11-27 Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Country Status (4)

Country Link
US (1) US20230374072A1 (es)
EP (1) EP4253399A1 (es)
MX (1) MX2020012914A (es)
WO (1) WO2022114946A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2638173T3 (da) * 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
RU2763320C2 (ru) * 2016-01-13 2021-12-28 Регенерон Фармасьютикалз, Инк. Грызуны, имеющие сконструированный участок разнообразия тяжелой цепи

Also Published As

Publication number Publication date
US20230374072A1 (en) 2023-11-23
EP4253399A1 (en) 2023-10-04
WO2022114946A1 (es) 2022-06-02

Similar Documents

Publication Publication Date Title
US20200199252A1 (en) Antibodies to MASP-2
CN105722992B (zh) 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
PH12019550087A1 (en) Anti-cd73 antibodies and uses thereof
JP2019000116A (ja) 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
CA2977350A1 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
JP6564777B2 (ja) 多量体ＩｇＡ型遺伝子組換え抗体を含む組成物及びその利用
NZ781143A (en) Anti-vegf protein compositions and methods for producing the same
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
US20230280354A1 (en) Methods for characterizing disulfide bonds
JP2018518475A (ja) 中和抗インフルエンザ結合分子及びその使用
US20210040236A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
Xin et al. Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties
SG175716A1 (en) Method of controlling o-linked glycosylation of antibodies
KR20240007256A (ko) 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2020012914A (es) Proteina andamio para la generacion de proteinas quimericas de union a antigeno.
US10406197B2 (en) Substances and methods for the use in prevention and/or treatment in Huntington's disease
MX2020010422A (es) Alfa-amilasa maltogenica variante.
KR101732534B1 (ko) 인플루엔자 a 바이러스에 대한 인간 항체
US20200369784A1 (en) Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
WO2014201400A2 (en) Anti-factor viii antibodies or uses thereof
US10371703B2 (en) Antibodies that inhibit long interspersed element-1 retrotransposon endonuclease activity
Fu et al. Preparation and identification of monoclonal antibodies against daintain
JP6918305B2 (ja) インフルエンザウイルスの増殖を阻害するモノクローナル抗体